Debiopharm acquires antibody-drug conjugate compound from ImmunoGen

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Debiopharm International and ImmunoGen, Inc. announced that Debiopharm has acquired ImmunoGen’s IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas.

Under the agreement, ImmunoGen received a $25 million upfront payment for IMGN529/DEBIO 1562 and is entitled to a $5 million milestone payment to be paid after completion of the transfer of ImmunoGen technologies related to the asset, which the parties expect to achieve by the end of 2017.

In addition, ImmunoGen is eligible for a second success-based milestone payment of $25 million upon IMGN529/DEBIO 1562 entering a phase III clinical trial.

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login